155 related articles for article (PubMed ID: 37629294)
1. Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings-Real-World Data.
Wieczorek A; Żebrowska U; Ussowicz M; Sokół A; Stypińska M; Dembowska-Bagińska B; Pawińska-Wąsikowska K; Balwierz W
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629294
[TBL] [Abstract][Full Text] [Related]
2. Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma.
Wieczorek A; Zaniewska-Tekieli A; Ehlert K; Pawinska-Wasikowska K; Balwierz W; Lode H
Front Oncol; 2023; 13():1082771. PubMed ID: 36816982
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
4. Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
Lode HN; Ladenstein R; Troschke-Meurer S; Struppe L; Siebert N; Zumpe M; Ehlert K; Huber S; Glogova E; Hundsdoerfer P; Eggert A; Zaniewska-Tekieli A; Balwierz W; Wieczorek A
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444475
[TBL] [Abstract][Full Text] [Related]
5. Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia.
Giljević JS; Rajačić N; Mikulić D; Batoš AT
Children (Basel); 2022 Jun; 9(7):. PubMed ID: 35883927
[TBL] [Abstract][Full Text] [Related]
6. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.
Olgun N; Cecen E; Ince D; Kizmazoglu D; Baysal B; Onal A; Ozdogan O; Guleryuz H; Cetingoz R; Demiral A; Olguner M; Celik A; Kamer S; Ozer E; Altun Z; Aktas S
Front Oncol; 2022; 12():1041443. PubMed ID: 36620564
[TBL] [Abstract][Full Text] [Related]
7. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
Lerman BJ; Li Y; Carlowicz C; Granger M; Cash T; Sadanand A; Somers K; Ranavaya A; Weiss BD; Choe M; Foster JH; Pinto N; Morgenstern DA; Rafael MS; Streby KA; Zeno RN; Mody R; Yazdani S; Desai AV; Macy ME; Shusterman S; Federico SM; Bagatell R
J Clin Oncol; 2023 Jan; 41(3):508-516. PubMed ID: 36206505
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review.
Mohd AB; Mohd OB; Alabdallat YJ; Al Dwairy SY; Ghannam RA; Hanaqtah BM; Albakri KA
J Res Med Sci; 2023; 28():71. PubMed ID: 38116487
[TBL] [Abstract][Full Text] [Related]
9. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
[TBL] [Abstract][Full Text] [Related]
10. Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Lode HN; Ehlert K; Huber S; Troschke-Meurer S; Siebert N; Zumpe M; Loibner H; Ladenstein R
Br J Cancer; 2023 Nov; 129(11):1780-1786. PubMed ID: 37813959
[TBL] [Abstract][Full Text] [Related]
11. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Greenwood KL; Foster JH
Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma.
Ehlert K; Hansjuergens I; Zinke A; Otto S; Siebert N; Henze G; Lode H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414861
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
14. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
15. Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava.
Achbergerová M; Hederová S; Hrašková A; Kolenová A
Medicine (Baltimore); 2022 Jan; 101(4):e28716. PubMed ID: 35089239
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman MJ; Dvorkin M; Laktionov K; Navarro A; Juan-Vidal O; Kozlov V; Golden G; Jordan O; Deng CQ; Bentsion D; Chouaid C; Dechev H; Dowlati A; Fernández Núñez N; Ivashchuk O; Kiladze I; Kortua T; Leighl N; Luft A; Makharadze T; Min Y; Quantin X;
Lung Cancer; 2022 Apr; 166():135-142. PubMed ID: 35278766
[TBL] [Abstract][Full Text] [Related]
17. Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction.
Cupit-Link M; Federico SM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760578
[TBL] [Abstract][Full Text] [Related]
18. Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse.
Flaadt T; Ebinger M; Schreiber M; Ladenstein RL; Simon T; Lode HN; Hero B; Schuhmann MU; Schäfer J; Paulsen F; Timmermann B; Eggert A; Lang P
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834840
[TBL] [Abstract][Full Text] [Related]
19. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
McGinty L; Kolesar J
Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
[TBL] [Abstract][Full Text] [Related]
20. Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma.
Balaguer J; García Hidalgo L; Hladun R; Márquez Vega C; Pérez Alonso V
Target Oncol; 2023 Jan; 18(1):77-93. PubMed ID: 36504394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
